Sexual and Reproductive Function in Chronic Kidney Disease and Effect of Kidney Transplantation by Lessan-Pezeshki, Mahboob & Ghazizadeh, Shirin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
13 
Sexual and Reproductive Function in  
Chronic Kidney Disease and Effect of  
Kidney Transplantation 
Mahboob Lessan-Pezeshki1 and Shirin Ghazizadeh2 
1Nephrology Research Center, Imam Khomeini Hospital,  
Tehran University of Medical Sciences, 
2Obstetrics and Gynecology Department,  
Tehran University of Medical Sciences,  
Iran  
1. Introduction 
Chronic renal failure has been known to be associated with impotence and loss of libido in 
men and for many women, infertility and menstrual irregularities. There have been ongoing 
improvements in survival and quality of life after renal transplantation. These have been 
accompanied by an improvement in reproductive function and reversal of the relative 
infertility that occurs despite maintenance hemodialysis. One of the most impressive aspects 
of successful renal transplantation in the young person is the ability of the male patient to 
father a child and the female patient to give birth to a healthy baby.  
Pregnancy does not appear to have any adverse effect on the long-term survival of renal 
allografts. Because the outcome of pregnancy in transplantation are so different than those 
in chronic dialysis, it is advisable to treat end-stage renal disease patients with 
transplantation and wait until renal function has been stable before undertaking a planned 
pregnancy. Women are usually advised to wait at least 1 year after living-related kidney 
Transplantation, and 2 years after cadaveric kidney transplantation; however, waits of 5 
years or more have been associated with impaired renal function post-partum.  
All women of child-bearing age should be counseled about the possibility and risks of 
pregnancy after kidney transplantation. Types of immunosuppressive regimens and 
assessment of graft function should be considered during preconception counseling. 
Contraceptive counseling should be provided before transplantation surgery, because 
ovulatory cycles may begin within 1 to 2 months after transplantation in women with grafts 
that are functioning well. It is strongly advised that every sexually active transplant 
recipient attend a family-planning counseling session, ideally before transplantation is 
performed. Breastfeeding is discouraged for patients taking any immunosuppressive drugs. 
In this chapter we will first have a short review on reproductive physiology in male and 
female and irregularities caused by end stage renal disease and then we will review the 
experience of women undergoing child birth after transplantation, with a focus on outcomes 
and suggested management strategies including contraception counseling. 
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2. Male reproduction 
2.1 Physiology of reproduction in men 
The male reproductive tract consists of the testis, epididymis, vas deference, prostate, 
seminal vesicles, ejaculatory duct, bulbouretral glands, and urethra. The testes contain two 
cell types: the Sertoli cells, which line the seminiferous tubules (the site of spermatogenesis), 
and the Leydig cells (the site of androgen synthesis). In the male, the pituitary gland secretes 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which act on the testes. 
LH stimulates the synthesis and secretion of testosterone by the Leydig cells, and FSH 
stimulates the sertoli cells to secrete inhibin. FSH and testosterone act on the seminiferous 
tubules to stimulate spermatogenesis. In human it takes about 75 days for spermatogonia to 
develop into mature sperm cells (Berek 2002).  
During ejaculation, mature spermatozoa are released from the vas deferens along with fluid 
from the prostate, seminal vesicle, and the bulbourethral glands. The semen released is a 
gelatinous mixture of spermatozoa and seminal plasma; however it thins out 20 -30 minutes 
after ejaculation by a process called liquefaction (Berek 2002). 
Both LH and FSH play roles in normal spermatogenesis. Thus, spermatogenesis does not 
occur spontaneously in men who have hypogonadotropic hypogonadism of prepubertal 
onset. Spermatogenesis can be initiated in these men by the administration of human 
chorionic gonadotropin (hCG), which has potent LH effects, and an FSH preparation, such 
as human menopausal gonadotropin (hMG) ( Finkel 1985). 
2.2 Male reproduction in end stage renal disease  
For many male patients with renal failure, impotence and loss of libido have been seen 
frequently; these problems may improve but rarely normalize with the institution of 
maintenance dialysis, commonly resulting in a decreased quality of life ( Holdsworth 1978; 
Diemont 2000;  Rosas 2003). By comparison, a well-functioning renal transplant is much 
more likely to restore sexual activity; however, some features of reproductive function may 
remain impaired. 
The uremic milieu plays an important role in the genesis of sexual dysfunction in end stage 
renal disease. Psychologic and physical stresses that may contribute to disturbances in 
sexual function are also commonly present in patients with chronic renal failure 
( Holdsworth 1978; Steele 1996; Toorians, Janssen et al. 1997).  
2.2.1 Gonadal function 
Advanced chronic kidney disease is associated with impaired spermatogenesis and 
testicular damage ( Holdsworth 1977;  Holdsworth 1978). Semen analysis typically shows a 
decreased volume of ejaculate, oligo- or complete azoospermia, and a low percentage of 
motile sperm. Testicular histology shows reduced spermatogenic activity varying from 
decreased numbers of mature spermatocytes to complete aplasia of germinal elements. 
Other findings include damage to the seminiferous tubules, atrophy of Sertoli cells, and 
interstitial fibrosis and calcifications. 
The factors responsible for testicular damage in uremia are not well understood. It is 
possible that plasticizers in dialysis tubing, such as phthalate, may play a role in patients 
undergoing maintenance hemodialysis.  
Uremia also impairs gonadal steroidogenesis. The serum total and free testosterone 
concentrations are typically reduced, although the binding capacity and concentration of sex 
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hormone-binding globulin are normal ( Lim 1976;  Levitan 1984; de Vries 1984). Another 
manifestation of diminished testosterone secretory capacity is the subnormal and delayed 
testosterone response to the administration of human chorionic gonadotropin (HCG), a 
compound with luteinizing hormone-like actions (Stewart-Bentley 1974). By comparison, 
although the total plasma estrogen concentration is frequently elevated, the serum estradiol 
concentration is typically normal (Lim 1978). 
2.2.2 Pituitary function 
The serum concentration of luteinizing hormone (LH) is elevated in uremic men (Lim 1978); 
this is due to diminished testosterone feedback.  
Follicle stimulating hormone (FSH) secretion is also elevated, although to a more variable 
degree ( Holdsworth 1978; de Vries 1984). Elevated FSH levels are probably the result of 
decreased testosterone and inhibin, a Sertoli cell product. The plasma FSH concentration 
tends to be highest in those uremic patients with the most severe damage to seminiferous 
tubules and presumably the lowest levels of inhibin. It has been suggested that increased 
FSH levels may portend a poor prognosis for recovery of spermatogenic function after renal 
transplantation. The gonadotropin reserve is generally intact, since the plasma level of both 
gonadotropins increased appropriately following administration of gonadotropin-releasing 
hormone (GnRH) (LeRoith 1980). The appropriate increase in FSH and LH in response to the 
administration of clomiphene (a nonsteroidal antiestrogen that stimulates gonadotropin 
secretion by blockade of estrogen mediated negative feedback on the hypothalamus) (Lim 
1978), also indicates a normal gonadotropin reserve.  
2.2.3 Hyperprolactinemia 
The basal levels of serum prolactin are elevated in the majority of uremic patients, and the 
response to thyrotropin-releasing hormone (TRH) is reduced and delayed (Hagen C 1976). 
The mechanisms for the hyperprolactinemia in chronic renal failure are not well defined. 
Increased autonomous production rate of prolactin is a major mechanism for the 
hyperprolactinemia but decreased metabolic clearance rate may also play a role (Cowden 
1981). The demonstration of resistance to stimulation or suppression of prolactin in CRF is 
consistent with increased autonomous production (Pece 1979). The state of secondary 
hyperparathyroidism of CRF may contribute to the increased production rate of prolactin, 
because PTH stimulates prolactin secretion (Issac 1978). The treatment of CRF patients with 
erythropoietin was associated with a decreased in serum prolactin levels and improvement 
in sexual dysfunction (Schaefer, Stanhope et al. 1989), but did not normalize rate of the 
response to TRH (Ramirez 1976). These observations suggest that either anemia and/or 
deficiency of erythropoietin per se participate in the genesis of the hyperprolactinemia of 
CRF. 
2.2.4 Gynecomastia 
Variable degrees of gynecomastia are often encountered in the male uremic patient treated 
with maintenance hemodialysis (Lim 1978). Gynecomastia  usually develops during initial 
months of dialysis and regresses as dialysis continues. It may be transient or may last for 
periods of several months. The etiology may be related to the improvement in the 
nutritional status of uremic patient with dialysis theray and, as such, is similar to the 
mechanism of refeeding gynecomastia. It must be emphasized that in almost all cases of 
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Gynecomastia, there is an alteration either in the ratio between the serum level of androgen 
and estrogen, in favor of the latter, or in the ratio between the action of androgen and 
estrogen at the tissue level ( Sawin 1973). Indeed, in patients with advanced CRF and those 
treated with hemodialysis, the ratio between the serum levels of free testosterone and 
estradiol is reduced because of a decreased in testosterone levels. 
2.3 Erectile dysfunction in end stage renal disease:   
Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient 
to permit satisfactory sexual intercourse. It may result from psychologic, neurologic, 
hormonal, arterial or cavernosal impairment or from a combination of these factors. Most of 
the studies in sexual dysfunctions in CRF patients have focused on impotence. Erectile 
dysfunction is common in patients with CRF and is observed in excess of 50% of these 
patients (Procci 1981). These data are based on results obtained from interviews with or by 
the completion of questionnaires by the patients and/or their spouses. Several factors 
appear to participate in the genesis of impotence in CRF patients. These include 
abnormalities in the neurohormonal control system of erection hormones of the 
hypothalamic-pituitary-gonadal axis , secondary hyperparathyroidism and, dysfunction of 
the corporal smooth muscle of the penis or in their response to relaxing stimuli and/or 
derangements in the arterial supply or the venous drainage of the penis (Schrier RW 2001). 
Patients with a history of abnormal erectile function prior to the onset of renal disease may 
have a secondary cause, such as a neuropathy or peripheral vascular disease.  
The presence of a neurogenic bladder suggests an underlying neuropathy, while findings of 
peripheral vascular disease point toward inadequate penile blood flow. The lack of 
secondary sexual characteristics combined with small soft testicles suggests hypogonadism. 
The ingestion of a number of medications, such as beta blockers and tricyclic 
antidepressants, may be a cause of erectile dysfunction.  
Among those without an obvious cause of impotence after an initial evaluation, 
consideration should be given to a psychologic difficulty, such as stress or depression. The 
values of Nocturnal Penile Tumescence (NPT) among a large population of uremic patients 
are significantly lower than normal. The administration of a nocturnal penile tumescence 
test may help distinguish between an organic and a psychologic disorder; the absence of an 
erection during sleep suggests underlying organic dysfunction. A positive test, however, 
does not exclude a physical cause. 
2.3.1 Management 
The first step in the treatment of uremic men with sexual dysfunction is increasing the 
delivered dose of dialysis, discontinuing medications with side effects of impotence and 
correcting the anemia of chronic renal disease. As an example, the administration of 
recombinant human erythropoietin to raise the hematocrit to 33 to 36 percent may enhance 
sexual function ( Delano 1989).   
Sildenafil has been effectively used in the treatment of erectile dysfunction in both 
hemodialysis and peritoneal dialysis patients and is often used for psychologic, vascular, or 
neurogenic causes ( Ifudu 1998; Palmer 1999;  Turk 2001; Seibel 2002;  Rosas 2003;  Grossman 
2004). Concurrent use of sildenafil and nitrates in any form, regularly or intermittently, is 
contraindicated. 
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Since the elevation of serum levels of prolactin plays a role in the impotence of male uremic 
patient, correction of hyperprolactinemia by bromocriptin is also associated with 
improvement of sexual dysfunction.  
Cabergoline, which causes nausea much less often than does bromocriptine and is at least as 
effective in treating hyperprolactinemia, should be tried first (Biller BM; Molitch ME; Vance 
ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A 1996 ). The 
administration of testosterone to uremic men usually fails to restore libido or potency, 
despite normalized serum testosterone. 
A vacuum tumescence device may be effective in restoring potency in uremic impotent 
males unresponsive to medical therapy. Administration of zinc is also a reasonable 
therapeutic option in uremic men.  
2.4 Renal transplantation 
Kidney transplantation is the best and most effective option that can be offered to patients 
with severe renal damage to restore their health and the possibility of recovering their 
sexual and reproductive functions. 
After successful transplantation, about two thirds of male patients observe improved libido 
and a return of sexual function to predialysis levels.  Fertility as assessed by sperm counts, 
improves in half patients. The sex hormone profile tends to normalize; plasma testosterone 
and follicle stimulating hormone levels increase; and luteinizing hormone levels which may 
be high in dialysis patients, decrease to normal or low levels (Danovitch GM 2005).  
The factors that might cause certain difficulties for the recovery of sexual and reproductive 
functions in this type of patients include prolonged use of peritoneal dialysis, high follicle 
stimulating hormone (FSH) serum levels before the transplant, and a deficient function of 
the graft (De Celis and Pedron-Nuevo 1999).  
A certain improvement has been reported as to semen quality in the three main parameters 
(number, morphology, and motility of the spermatozoa) in patients after kidney 
transplantation (De Celis and Pedron-Nuevo 1999). 
Several studies conducted to evaluate the effects of immunosuppressive regimens suggest 
that some of these agents are potentially gonadotoxic since they affect testicular function 
and decrease fertility. This is mainly due to an indirect effect on the hypothalamus–
pituitary–gonadal axis, or directly suppressant on the germinal epithelium of the testis, 
where the spermatogenetic process is primarily affected because of an interruption of the 
cycle needed for the development of an adequate amount of normal spermatozoa. 
This would result in oligo/asthenozoospermia, teratozoospermia, or azoospermia. 
Cyclosporine (CSA) is an important therapeutic agent and a common component in 
multiple immunosuppressive regimens used in recipients of kidney transplants and for a 
growing number of autoimmune disorders. Some studies imply that CSA is a potentially 
gonadotoxic drug, producing adverse effects on the reproductive capability in experimental 
models as well as in humans. In certain animal species, such as the Sprague–Dawley strain 
rats, Seethalakshmi et al. showed that the administration of CSA induces a deficient 
intratesticular synthesis of androgens and a reduction in spermatogenesis, although this 
reduction was reversible after exogenous gonadotrophins were administered 
(Seethalakshmi 1990). On the other hand, it has also been possible to observe the adverse 
effect of CSA by means of testicular biopsies performed in dogs (Seethalakshmi 1988) and 
rats (Seethalakshmi 1990) treated with CSA for short periods, where marked abnormalities 
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in spermatogenesis were seen. Cyclosporine (CSA) may impair testosterone biosynthesis 
through direct damage to leydig cells and germinal cells, an indirect impairment of the 
hypothalamic-pituitary-gonadal axis has also been suggested.  
Computer-aided sperm analysis (CASA) in infertile renal transplant recipients showed that 
both sperm concentration and straight line velocity (VSL) were inversely correlated to the 
cyclosporine whole blood trough levels. Stabilization of the cyclosporine whole blood 
trough level within the target therapeutic level could improve the fertility potential in 
kidney transplant recipients. Duration of hemodialysis before transplantation is also 
important in this regard. The time spent on hemodialysis is inversely correlated with the 
percentage of motile spermatozoa and the amplitude of lateral head displacement (ALH) 
(Eid, Abdel-Hamid et al. 1996). 
Azathioprine (AZA), another drug that is frequently combined with CSA, is considered to 
be genotoxic (Olshan 1994). However, very few studies have analyzed the effects of AZA on 
the reproductive function of humans. Several studies suggest that prednisone might not be 
involved in sperm cell damage. 
Kaczmarek and coworkers found that heart transplant recipients treated with sirolimus had 
significantly lower free testosterone levels and significant higher levels of gonadotropic 
hormones luteinizing hormone and follicle-stimulating hormone compared with calcineurin 
inhibitor-based immunosuppression group (Kaczmarek 2004). Patients treated with 
sirolimus throughout the post-transplant period have a significantly reduced total sperm 
count compared to patients who did not receive sirolimus and a decreased proportion of 
motile spermatozoa. Moreover, the fathered pregnancy rate was lower in patients receiving 
sirolimus-based regimens (Zuber, Anglicheau et al. 2008). 
There is also concern about infertility associated with Ganciclovir which is used for 
treatment of cytomegalovirus (CMV) infection in transplant patients (Nevins and Dunn 
1992). There is no increased incidence of neonatal malformations in pregnancies fathered by 
transplant recipients (Danovitch GM 2005). 
2.4.1 Sexual functions in renal transplant patients 
Renal transplant recipients have all suffered from uremia. They have frequently spent a 
significant amount of time on dialysis and often have other comorbidities including 
hypertension and diabetes. Although a successful transplant may improve erectile function 
and return of libido, in many cases some degree of sexual dysfunction may persist. On the 
contrary a recent study showed that, erectile function worsens after RT in patients<45 yr 
(Mirone, Longo et al. 2009).  
Hypertension is common among transplant patients; CSA can exacerbate preexisting high 
blood pressure and also induce hypertension in patients, who had normal blood pressure 
prior to the kidney transplant. 
Antihypertensive medications have negative effects on male sexual functions, such as libido 
and erection (Matthew RW 2005). Those medications which are implicated in erectile 
dysfunction include beta blockers (propranolol, labetalol), Alpha blockers (prazosin), 
sympatholytics (clonidine), vasodilators (hydralazine), and diuretics (thiazides, 
spironolactone).  
Other drugs which may also play a role in erectile dysfunction in transplant patients are: 
HMG- CoA reductase inhibitors (lovastatin, simvastatin), antidepressant (serotonin 
reuptake inhibitors, tricyclics, monoamine oxidase inhibitors) and H2 antagonists 
(cimetidine, ranitidine, famotidine).  
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Ketoconazole which is used in some transplant centers in order to increase cyclosporine 
level and reducing the cost of calcineurin inhibitors can cause erectile dysfunction because 
of its antiandrogenic action. 
Additional factors such as smoking and alcohol intake may account for failure of male 
sexual function to improve after transplantation.  
Cigarette smoking may induce vasoconstriction and penile venous leakage because of its 
contractile effect on the cavernous smooth muscle (Juenemann 1987). Alcohol in small 
amounts improves erection and increases libido because of its vasodilatory effect and the 
suppression of anxiety; however, large amounts can cause central sedation, decreased libido, 
and transient erectile dysfunction. Chronic alcoholism may cause hypogonadism and 
polyneuropathy, which may affect penile nerve function (Miller 1988). 
Autonomic neuropathy may impair erectile function, and interruption of both hypogastric 
arteries may occasionally impair vascular supply. 
2.4.2 Management of erectile dysfunction in transplant patients 
Male patients should be asked about their sexual function and referred for urologic 
evaluation when necessary. Historically, androgens were touted as enhancing male sexual 
function. Today, more effective treatments are available, and testosterone therapy should be 
discouraged in men in whom erectile dysfunction is not associated with hypogonadism (Lue 
T F 2000). Sildenafil is a selective inhibitor of phosphodiesterase type 5, which inactivates 
cyclic GMP. Since its release in March 1998, it has become the drug of choice for most men 
with erectile dysfunction. When sexual stimulation releases nitric oxide into the penile 
smooth muscle, inhibition of phosphodiesterase type 5 by sildenafil causes a marked 
elevation of cyclic GMP concentrations in the glans penis, corpus cavernosum, and corpus 
spongiosum, resulting in increased smooth-muscle relaxation and better erection. Sildenafil 
has no effect on the penis in the absence of sexual stimulation, when the concentrations of 
nitric oxide and cyclic GMP are low (Lue T F 2000). Sildenafil has little effect on libido. 
Among more than 3700 men with 1631 patient years of exposure to sildenafil, most adverse 
events were mild to moderate and self-limited in duration (Esteban de la Rosa, Bravo Soto et 
al. 2003). Among men taking 25 to 100 mg of sildenafil, 16 percent reported headache, 10 
percent flushing, 7 percent dyspepsia, 4 percent nasal congestion, and 3 percent abnormal 
vision (described as a mild and transient color tinge or increased sensitivity to light). These 
rates were twice as high among men taking 100 mg of sildenafil as among men who were 
taking lower doses. The visual effect is probably related to inhibition of phosphodiesterase 
type 6 in the retina. No chronic visual impairment has been reported, and the incidence of 
visual side effects was similar in diabetic and nondiabetic men (Price 1998). Nevertheless, 
because of the short duration of the clinical trials and the difficulty in detecting subtle retinal 
changes, the long-term safety of sildenafil treatment is still unknown. In men with retinal 
diseases, an ophthalmologic consultation may be warranted before sildenafil treatment is 
initiated. Adverse cardiovascular events (nasal congestion, headache, and flushing) were 
mild and transient in the majority of men. The rate of serious cardiovascular events (angina 
and coronary-artery disorder) is low. Sexual activity was thought to be a likely contributor 
to myocardial infarction in only 0.9 percent of 858 men in one study (Muller, Munder et al. 
2009). Thus, the absolute increase in risk caused by sexual activity is low (one chance in a 
million for a healthy man). According to data from the National Center for Health Statistics 
and the Framingham Heart Study, the rate of death from myocardial infarction or stroke for 
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men in the age range in which erectile dysfunction is common is approximately 170 per 
million men per week. Therefore, it appears that sildenafil therapy is safe for most men. 
Nevertheless, given that most of the men who died had underlying cardiovascular disease; 
cardiovascular status should be carefully assessed before treatment. The combination of 
nitrates and sildenafil has resulted in severe hypotension and 16 deaths in the United States. 
Therefore, nitrate therapy is an absolute contraindication to sildenafil therapy (Lue T F 
2000).  
Sildenafil is absorbed well during fasting, and the plasma concentrations are maximal 
within 30 to 120 minutes (mean, 60). It is eliminated predominantly by hepatic metabolism, 
and the terminal half-life is about four hours. The recommended starting dose is 50 mg taken 
one hour before sexual activity. The maximal recommended frequency is once per day. On 
the basis of effectiveness and side effects, the dose may be increased to 100 mg or decreased 
to 25 mg (Lue T F 2000). There is no specific contraindication to use of sildenafil (Viagra) in 
transplant patients so long as standard precautions are taken regarding concomitant 
coronary artery disease.  
Oral vardenafil  (Phosphodiesterase-5 Enzyme Inhibitor) therapy has a high efficacy and a low 
incidence of adverse events for kidney transplant recipients with ED (Yang, Ju et al. 2008).  
Vardenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is 
responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation 
causes local release of NO, inhibition of PDE-5 by vardenafil causes increased levels of cGMP 
in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the 
corpus cavernosum. so it can prolong erectile duration of ED patients (Wang and Huang 2009); 
at recommended doses, it has no effect in the absence of sexual stimulation. 
Transurethral administration of alprostadil (synthetic form of prostaglandin E1) or 
intracavernous injection resulting in an erection sufficient for intercourse has been used 
successfully. The most effective intracavernous therapy used is a three-drug mixture 
containing papaverine, phentolamine, and alprostadil (trimix). The usual dose of trimix 
solution ranges from 0.1 to 0.5 ml. The rate of response to this solution is as high as 90 
percent (Bennett 1991). In case of drug treatment failure, penile prosthesis can be considered 
even in transplanted patients (Lasaponara, Pasquale et al. 2009; Phe, Roupret et al. 2009). 
3. Female reproduction 
3.1 Menstrual cycle 
The menstrual cycle is a hormonally controlled process of events occurring through the 
hypothalamic-pituitary-ovarian axis and reflected by the histological changes in the 
endometrium.    
The normal menstrual cycle is a tightly coordinated cycle of stimulatory and inhibitory 
effects that results in the release of a single mature oocyte from a pool of hundreds of 
thousands of primordial oocytes.  
The menstrual cycle lasts 25 to 30 days in most women. It is divided into two successive 
phases: the follicular phase and the luteal phase. By convention, the day of menstruation is 
designated as day 1 of the menstrual cycle. The luteal phase is remarkably constant in length 
and lasts 13 to 15 days, but length of the follicular phase is variable. The average duration of 
flow is 4 to 6 days but can be as few as 2 days and as many as 7 days. A flow of longer than 
7 days deserves evaluation (Higham 1990).The average blood loss during one menses is 
about 30 mL. A flow of 80 mL or more can lead to anemia and should be evaluated (Cohen 
www.intechopen.com
 
Sexual and Reproductive Function in Chronic Kidney Disease and Effect of Kidney Transplantation 
 
237 
and Galbraith 2001). However, it is not necessary to measure menstrual flow; a patient's 
perception of abnormal menses deserves evaluation and treatment.  
By definition menorrhagia is excessive and prolonged uterine bleeding at regular intervals; 
metrorrhagia is irregular, intermenstrual bleeding. Menometrorrhagia is heavy, prolonged, 
irregular bleeding at frequent, irregular intervals. Polymenorrhea is frequent, regular 
episodes of uterine bleeding at intervals of less than 21 days. Oligomenorrhea is irregular 
bleeding occurring at prolonged intervals of more than 35 days. Amenorrhea is absence of 
uterine bleeding (Sciarra J 2001). 
There is relatively little cycle variability among women between the ages of 20 and 40 years. 
In comparison, there is significantly more cycle variability for the first 5 to 7 years after 
menarche and for the last 10 years before cessation of menses (Treloar 1967). 
3.2 Menstrual cycle irregularities in end stage renal disease 
Menstrual problem is common among women with renal insufficiency. It is partly because 
of abnormal bleeding time due to platelet dysfunction and also because of failure to ovulate 
or sustain adequate corpus luteum function.  
Amenorrhea is common by the time the patient reaches end-stage renal disease. The 
menstrual cycle typically remains irregular with scanty flow after the initiation of 
maintenance dialysis, although normal menses are restored in some women( Holley 1997) In 
others, menorrhagia develops, sometimes leading to significant blood loss and increased 
transfusion requirements.  
Oligo/ anovulation is the major factor for these menstrual cycle abnormalities in uremic 
women. Uremia is associated with hypothalamic-pituitary-gonadal dysfunction.  
Leptin is one of the responsible factors involving in this cycle abnormality. In general, serum 
leptin levels are significantly elevated in patients with renal failure, particularly when 
compared to age and body mass index (BMI)-matched controls ( Wolf 2002). Leptin appears 
to be one of several factors that influence the maturation of the gonadotropin-releasing 
hormone (GnRH) pulse generator. 
Hyperprolactinemia is common in women with chronic renal failure due to increased 
secretion and decreased metabolic clearance of this hormone ( Sievertsen 1980). The elevated 
prolactin levels may impair hypothalamic-pituitary function and contribute to sexual 
dysfunction and galactorrhea in these patients. Although kidney transplantation greatly 
improves menstrual pattern, but irregular bleeding is still a major problem among women 
with a transplanted kidney. In a study on 114 women with a transplanted kidney we found 
normal menstruation in 49%, oligo/ hypomenorrhea or amenorrhea in 31.3% and 
hypermenorrhea in 19.8% (Lessan-Pezeshki, Ghazizadeh et al. 2004).  
 In order to reduce the chance of endometrial hyperplasia that results from chronic 
stimulation of the endometrium with estradiol, medroxyprogesterone acetate (Provera), 10 
mg/day orally for 5 days is prescribed. Patients with adequate endogenous estrogens will 
bleed within 3 to 5 days after medication, indicating adequate endogenous estrogen 
stimulation of the endometrium. Patients with relatively low levels of endogenous estrogens 
may have a limited response to the progesterone challenge. 
3.3 Sexual dysfunction in uremic women 
Sexual desire or drive is defined as the frequency or intensity with which a person desires to 
participate in sexual activity. Both organic and psychological variables contribute to this 
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interest. Hormones can act on sexual behavior indirectly by influencing general mood. They 
can influence sexual interest levels by their peripheral action, such as by increasing genital 
vasocongestion and sexual sensation or by enhancing the sexual attractiveness of the female 
by means of smell. Women receiving chronic dialysis tend to experience decreased libido 
and reduced ability to reach orgasm. 
Uremic patient's sexual difficulties are often worsened by hemodialysis, with a lowered 
frequency of intercourse, reduced sexual desire, and an increased incidence of sexual failure 
(Thurm JA 1976 ). Initial treatment goals for uremic women with sexual dysfunction include 
increasing the adequacy of dialysis, and correcting the anemia of chronic renal failure.  
Amenorrheic dialysis patients may have low estradiol levels; this may lead to vaginal 
atrophy and dryness, thereby resulting in discomfort during intercourse. Such patients may 
benefit from local estrogen therapy or vaginal lubricants. Successful transplantation is 
clearly the most effective means to restore normal sexual desire in women with chronic 
renal failure ( Diemont 2000). Sexual desire increases significantly after successful 
transplantation in most patients, however improvement in frequency of sexual activity and 
overall sexual satisfaction is not as high as sexual desire. 
Low dose testosterone may be effective but, due to potential toxicity, is rarely used. The 
administration of bromocriptine may help restore sexual function in those with 
hyperprolactinemia.  
3.4 Pregnancy in end stage renal disease 
Fertility is reduced in the presence of end-stage renal disease. Conception is rare for women 
on dialysis, and occurs at a rate of one in every 200 patients (Rizzoni, Ehrich et al. 1992). 
Pregnancy is often diagnosed late because of menstrual irregularities; thus, early 
spontaneous abortion may be overlooked. The diagnosis of pregnancy may be difficult in 
women with end-stage renal disease; particularly because serum levels of beta-human 
chorionic gonadotropin (beta-hCG) may be increased in the absence of pregnancy. The main 
risks for a fetus include death, prematurity, and growth retardation. A review by Hou of 37 
pregnancies associated with chronic renal dialysis found that 75% to 80% resulted in 
spontaneous abortion, stillbirth, or neonatal death. (Hou S 1987) Placental abnormalities 
included abruption, infarction, and microscopic areas of necrosis. No developmental 
abnormalities were reported, and the incidence of congenital abnormalities appeared to be 
no greater than for normal pregnancies.  
Hypertension is a major problem and may prove very difficult to control. Forty-nine percent 
of the patients reviewed by Hou became hypertensive during pregnancy. The infants of 
hepatitis carriers should receive hepatitis B immune globulin and vaccine in the first 72 
hours to avoid becoming carriers. 
Since 1976, chronic ambulatory peritoneal dialysis (CAPD) has been increasingly used to 
manage end-stage renal failure. It has several theoretical advantages over hemodialysis for the 
management of pregnant patients (Mahanty, Cherikh et al. 2001). A more constant intrauterine 
environment without rapid shifts in fluid, solutes, and electrolytes may benefit a fetus, Redrow 
compared eight pregnancies managed with peritoneal dialysis with seven managed with 
hemodialysis (Redrow 1988 ). Hypotensive episodes appear to be less frequent, hematocrits 
higher, and control of insulin and glucose levels more exact in the group on peritoneal dialysis. 
Further experience is needed to determine if this is the preferred mode of dialysis in 
pregnancy. If peritoneal dialysis is used, the exchange volumes should be decreased (eg, to 1.5 
liters) and the frequency should be increased (Jungers and Chauveau 1997). 
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3.4.1 Management 
An increased dose of dialysis appears to be beneficial, with reports of Kt/V values of 6 to 8, 
on hemodialysis 5-6 days per week (Henrich WL 2004), with the BUN being maintained at 
under 50 mg/dL or even under 45 mg/dL. Ameliorating the uremic milieu can avoid 
polyhydramnios, help control hypertension, and improve maternal nutrition. Increased 
doses of erythropoietin are required to maintain hemoglobin levels in an acceptable range 
(10 to 11 g/dl) and transfusions are sometimes required (Chao 2002). Protein intake should 
be 1 g/kg per day plus an additional 20 g/day for fetal growth. Diet should be 
supplemented with water soluble vitamins and zinc. Metabolic acidosis and hypocalcemia 
should be corrected. Careful uterine and fetal monitoring during hemodialysis, such as 
assessment of the fetal heart rate (particularly during the last portion of a session), combined 
with measures aimed at preventing dialysis-induced hypotension should be performed. In 
many cases, patients are hospitalized around week 20 of gestation for management of blood 
pressure, dialysis fluid balance, nutrition and anemia. 
If peritoneal dialysis is used, the exchange volumes should be decreased (eg, to 1.5 liters) 
and the frequency should be increased. 
3.5 Pregnancy in renal transplantation 
Fertility is usually restored in women with renal transplants and pregnancy is common, 
occurring in 12% of women at childbearing age in one series (Sturgiss and Davison 1995). 
Pregnancy success rate exceeds 90% after the first trimester. The recovery of fertility is less 
common in women who undergo transplantation close to the end of their childbearing years 
(Hou S 1987). The first reported successful pregnancy occurred in a recipient of a kidney 
transplant from an identical twin sister performed in 1958 (Murray 1963). Since then, there 
have been hundreds of successful pregnancies reported in renal transplant recipients 
(Davison JM 1987). During the last decade there has been a steady increase in the number of 
pregnancies following renal transplantation (Sgro, Barozzino et al. 2002).  
Pregnancy in transplant recipients provides an opportunity to investigate biological 
processes that may have an impact on graft outcome as well as pregnancy outcome. For 
example, immunologic adjustments are believed to be involved in implantation as well as a 
successful acceptance of the allogenic fetus by their mother (Matthew RW 2005).  
3.5.1 Effect of pregnancy on graft function 
Although pregnancy can cause an increase in the glomerular filtration rate, which could 
theoretically lead to hyperfiltration and resultant glomerulosclerosis, the hyperfiltration of 
pregnancy is flow related, with no concomitant increase in intraglomerular pressure 
(Denton and Baylis 2007).  
In cyclosporine treated patients, graft dysfunction after pregnancy was seen in patients with 
higher mean serum creatinine levels and lower mean cyclosporine doses prior to conception 
(ArmentiVT, Radomski JS et al. 2000). Overall, in the majority of recipients studied, 
pregnancy does not appear to cause excessive or irreversible problems with graft function if 
the function of transplant organ is stable prior to pregnancy (Armenti, Constantinescu et al. 
2008).  
The long-term effect of pregnancy on renal function is less clear. Two small studies in which 
matched nonpregnant controls were used found conflicting results: no deleterious effect in 
one with 15 year follow-up; and an increase in the plasma creatinine concentration of 0.5 to 
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0.7 mg/dL at 3 to 12 months in the other (Salmela, Kyllonen et al. 1993; Sturgiss and 
Davison 1995). The latter report also suggested that a second pregnancy might carry a 
greater risk, as renal function deteriorated in three of seven women (Salmela, Kyllonen et al. 
1993).  
The incidence of acute rejection is not greater than expected for non-pregnant transplant 
patients. The incidence of acute rejection during pregnancy and three months after delivery 
varies between 9 and 14.5% in the published series. Rejection is sometimes difficult to 
diagnose and an ultrasound-guided biopsy may be helpful to diagnose acute pyelonephritis, 
recurrent glomerulonephritis, and severe pre-eclampsia. Renal biopsy should be performed 
before starting anti-rejection therapy, and high steroid doses are the first line of treatment. It 
has been suggested that acute rejection during the puerperium may be due to a return to a 
normal immune status or to a rebound effect from the altered gestational immune 
responsiveness. Therefore, immunosuppression should be re-adjusted immediately after 
delivery. 
3.6 Immunosuppressive drugs in pregnancy 
Immunosuppression in pregnancy is a concern from the perspective of both maternal and 
fetal safety issues. Blood volume and volume of distribution increase during pregnancy thus 
blood levels of immunosuppressive drugs are often lower, though there is no evidence that 
effective immunosuppression is inadequate if prepregnancy doses are used.   We currently 
have limited information regarding the toxicities and teratogenic potentials of these agents, 
although our knowledge has recently increased as more women maintained on 
immunosuppressive therapy for solid organ transplants have opted to become pregnant. 
3.6.1 Glucocorticoids 
The most commonly used glucocorticoids are the short acting agents; prednisone, 
prednisolone and methyl prednisolone. Radiolabaled prednisone and prednisolone can 
cross the placenta, but maternal / cord blood ratios are approximately 10:1 (Beitins 1972). In 
utero exposure to high-dose steroid and immunosuppressive agents does not seem to be 
associated with an increased incidence of congenital anomalies in the offspring of pregnant 
women with a renal transplant. Adrenal insufficiency and thymic hypoplasia have 
occasionally been described in the infants of transplant recipients, but these problems are 
unlikely if the dose of prednisone has been decreased to 15 mg . Cases of cleft palate, mental 
retardation, have also been described in humans after in utero corticosteroid exposure.  
Glucocorticoid therapy during pregnancy can result in premature rupture of the membranes 
(PROM) and intrauterine growth restriction. The increased risk of PROM with prednisone 
therapy likely reflects the inhibitory effects of glucocorticoids on fetal membrane 
extracellular matrix synthesis. Alternatively, PROM may be the result of prednisone's 
stimulatory effects on fetal membrane, placental, and decidual corticotropin releasing 
hormone. Furthermore, pregnancy-induced hypertension, gestational diabetes, and 
osteoporosis can be exacerbated. 
Doses of prednisone greater than 20 mg/d have been associated with serious maternal 
infection, however treatment of rejection with steroids, if necessary, should not be avoided 
during pregnancy (Lessan-Pezeshki M 2002). 
Current data suggest that steroids and immunosuppressive agents in the doses used to 
prevent graft rejection in transplant recipients are well tolerated by the fetus. Long-term 
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studies are required to determine whether there may be other effects, particularly an 
increase in the incidence of malignancies or abnormalities in the subsequent generation. 
FDA rates the risk of prednisone use in pregnancy as C which implies that "Risks can not be 
ruled out". 
3.6.2 Azathioprine 
Azathioprine is an antimetabolite, an imidazole derivative of 6- mercaptopurine . It is 
commonly used during pregnancy in transplant recipients. Radioactive labeling studies in 
humans have shown that 64 - 93 percent of azathioprine administered to mothers appears in 
fetal blood as inactive metabolites (Sarikoski 1973). Azathioprine can cause transient gaps or 
breaks in lymphocyte chromosomes. Germ cells and other tissues have not been studied. In 
the adult, azathioprine is metabolized to 6- mercaptopurine. The immature fetal liver lacks 
the enzyme inosinate pyrophosphorylase, needed for conversion, and the fetus is relatively 
protected from the effects of the drug (Lessan-Pezeshki M 2002). The desired drug dose of 
azathioprin is 2 mg/kg/day or less. In high doses (6 mg/kg), azathioprine is teratogenic in 
animals. In human studies low birth weights, prematurity, jaundice, respiratory distress 
syndrome and aspiration have been reported in kidney transplant recipients. Azathioprine 
has been associated with a dose related myelosuppression in the fetus, but leukopenia is not 
usually a problem in the neonate if the maternal white blood count is maintained at greater 
than 7500 /mm3 (Armenti, Constantinescu et al. 2008).  
FDA rated azathioprine use during pregnancy as D which implies that "positive evidence of 
risk exists but potential benefit may outweigh the risk" 
3.6.3 Cyclosporine 
Cyclosporine is a small cyclic polypeptide of fungal origin that inhibits calcineurin. There is 
little or no transplacental passage of cyclosporine in rodents (Safwenberg, Backman-Bave et 
al. 1977). In comparison, there are conflicting reports on the transfer of cyclosporine across 
the human placenta. Studies in pregnant rats have generally shown no effect of cyclosporine 
on organogenesis, although some renal proximal tubular cell damage can occur (Bailie, 
Elder et al. 2007). Human data showed that administration of cyclosporine was associated 
with low birth weights and a higher incidence of maternal diabetes, hypertension and renal 
allograft dysfunction. Cyclosporine metabolism appears to be increased during pregnancy 
and higher doses may be required to maintain plasma levels in the therapeutic range 
(Murirhead 1992). In women several years post-transplant with stable renal function, the 
pre-pregnancy dose can be continued. Some of the pregnancies in cyclosporine- treated 
women were complicated by preeclampsia. Cyclosporine increases production of 
thromboxane and endothelin, which have both been implicated in the pathogenesis of 
preeclampsia. Because of this, some physicians have suggested that the dose be limited to 2 
to 4 mg/kg per day (Lindheimer Md and 1992).  
Although the safety of cyclosporine is not well established in pregnancy, but it does not 
appear to be a major teratogen, as suggested by the results of a meta-analysis of 15 studies 
(Bar Oz 2001 ).  
FDA rates the risk of cyclosporine use in pregnancy as C. 
3.6.4 Tacrolimus 
Tacrolimus is another calcineurin inhibitor. Experience with tacrolimus in pregnancy is 
limited. Among 100 pregnancies in 84 women treated with tacrolimus, of whom 27 percent 
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were renal transplant recipients, 68 progressed to a live birth, with 60 percent of deliveries 
being premature (Kaniz and 2000). It has been associated with neonatal hyperkalemia. As 
with cyclosporine, patients taking tacrolimus require frequent monitoring of renal function 
and drug levels. During pregnancy, the hepatic cytochrome p450 enzymes may be inhibited, 
which can lead to increased serum level of tacrolimus. The dose may therefore have to be 
significantly reduced to prevent toxicity (sometimes as much as 60 %) (Lessan-Pezeshki M 
2002).  
FDA rates the risk of tacrolimus use in pregnancy as C. 
3.6.5 Mycophenolate Mofetil (MMF) 
MMF is a selective antimetabolite which impairs lymphocyte function by blocking purine 
biosynthesis via inhibition of the enzyme inosine monophosphate dehydrogenase. 
Mycophenolate was developed as a replacement for azathioprine for maintenance 
immunosuppression. It is not nephrotoxic, and has less bone marrow toxicity than 
azathioprine.  
MMF has been reported to cause head and eye malformations in the offspring of rat. 
Reported experience in human pregnancy with MMF is limited. There have been birth 
defects in few cases, but current data are insufficient to determine incidence of specific 
malformation. Among the 14 MMF-exposed offspring that has been reported, the 
underlying maternal conditions were kidney transplantation (N=7), lupus nephritis (N=4), 
liver transplantation, heart transplantation, and recurrent erythema multiforme. All were 
exposed in early pregnancy. The most distinctive malformation was moderate-to-severe 
microtia or anotia in 12, with external auditory canal atresia in 9. Other common craniofacial 
malformations and minor anomalies included orofacial clefts, hypertelorism, coloboma, and 
micrognathia. Six had cardiovascular malformations, of which three were either conotruncal 
or aortic arch defects (Anderka, Lin et al. 2009).  
The manufacturer of MMF recommends that women of child-bearing age should have a 
negative pregnancy test prior to the initiation of therapy. We currently recommend that 
allograft recipients who wish to conceive should change from MMF to azathioprine, if there 
are no contraindications to the switch. MMF should be stopped 6 weeks prior to conception. 
FDA rates the risk of MMF use in pregnancy as D. 
3.6.6 Sirolimus 
Sirolimus is a macrolide antibiotic compound that is structurally related to tacrolimus. 
Following entry into the cytoplasm, sirolimus binds to the FK binding protein and 
presumably modulates the activity of the mammalian target of rapamycin (mTOR). The 
mTOR inhibits interleukin-2 mediated signal transduction, resulting in cell cycle arrest in 
the G1-S phase (Danovitch GM 2005). It causes delayed ossification in animal reproductive 
studies, and its use is contraindicated in human until more data are available. Its use should 
also be discontinued at least 6 weeks prior to attempted conception.  
In general, we recommend that women post-transplant who wish to conceive be switched 
prior to conception from sirolimus to cyclosporine. Upon delivery, it is recommended  
to switch the mother back to her basal immunosuppression in view of the potential  
benefits of the newer agents to prevent late acute rejection and chronic allograft 
nephropathy.  
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FDA rates the risk of sirolimus use in pregnancy as C.  
3.6.7 OKT3 and polyclonal antibodies 
OKT3 is a mouse antibody licensed for antirejection therapy, being directed against the CD3 
antigen that is closely associated with the T cell receptor. It crosses the placenta. The 
National Transplantation Pregnancy Registry (NTPR) has reported the treatment of five 
women with OKT3 during pregnancy, with four surviving infants (Eisenberg 1997). The 
effect of polyclonal antibodies on the developing fetus is not known, but the IgG component 
would be expected to cross the placenta. 
3.6.8 Intravenous Immune Globulins (IVIG) 
Pooled human gamma-globulin preparations which were initially developed for the 
treatment of humoral immune deficiency disorders, proving to be invaluable in certain 
defined situations in clinical transplantation when used alone or in combination with 
plasmapheresis, such as antibody mediated rejection (Danovitch GM 2005). IgG is 
selectively transported across the placenta and the amount transferred increases with 
gestational age and dose. No cases of human deficiency virus (HIV) transmission have been 
reported with the use of IVIG, but adverse effects include thrombosis, alopecia, liver 
function disturbances, transient neutropenia, chills, nausea, flushing, tightness of chest and 
anaphylactic reaction in those with IgA antibodies. 
There is little information regarding the teratogenicity of IVIG in animals. One report 
showed that IVIG was well tolerated in pregnant mice with induced antiphospholipid 
antibody syndrome (Bakimer 1993). In humans, IVIG appears to cross the placenta after 32 
weeks of gestation, even after modification that alters the Fc binding sites ( Hockel 1986). 
There have been no reports of fetal malformations in humans. However, IVIG is not 
completely benign, since hemolytic disease of the newborn and transmission of hepatitis C 
has been reported in selected cases.        
3.6.9 Leflunomide 
Leflunomide is an antimetabolite with both immunosuppressive and antiviral activities. It 
has been used successfully in the treatment of polyoma virus nephropathy (Danovitch GM 
2005). It has marked teratogenic properties. 
FDA rates its use during pregnancy as X. This medication should not be used during 
pregnancy or breast feeding.  
3.7 Management of pregnancy in kidney transplant patient's guidelines: 
All women of childbearing age should be counseled concerning the possibility and risks of 
pregnancy after kidney transplantation. Women who are not rubella immune should receive 
the rubella vaccine before transplantation, because live virus vaccines are contraindicated 
post transplantation (Hou S and 1999). Women are usually advised to wait at least one year 
after living related donor transplantation and two years after cadaveric renal transplantation 
(Lessan-Pezeshki M 2002). However, waiting 5 or more years may result in impaired renal 
function post partum that fails to recover, because of gradually deteriorating renal function 
secondary to chronic allograft nephropathy. 
Criteria that should be ideally met before conception are shown in table 1. 
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At least 1 year post transplantation 
Stable renal function with creatinine< 1.5 mg/dl 
No recent episodes of acute rejection 
BP < 140/90 mmHg on medications 
Proteinuria <500 mg/ day 
Prednisone < 15 mg/day 
Azathioprine < 2 mg /kg/day 
Cyclosporine 2- 4 mg/ kg/ day 
Normal allograft ultrasound 
Table 1. Criteria for transplant recipients contemplating pregnancy 
3.7.1 Management of preeclampsia and chronic hypertension 
Preeclampsia is the most common complication, affecting 30% of pregnancies in renal 
transplant recipients, especially those with pre-transplant hypertension. Women with mild 
to moderate hypertension should be watched closely, warned about signs of early 
superimposed preeclampsia. 
In transplant recipients, changes in urinary protein excretion, plasma uric acid, platelet 
count, or liver function tests seem to be less useful as markers of preeclampsia than in the 
normal population. Blood pressure, renal function, proteinuria and weight should be 
monitored every 2-4 weeks, with more attention during the third trimester. Anti-
hypertensive agents should be changed to those tolerated during pregnancy.  
3.7.2 Antihypertensive drugs used in pregnancy 
Safety and efficacy of Alpha Methyldopa are supported in several randomized trials and in 
7.5 years follow up study of children born to treated mothers. 
Beta Blockers; especially Atenolol and Metoprolol, appear to be safe and efficacious in late 
pregnancy; but fetal growth retardation has been noted when treatment was started in early 
or midgestation (Lindheimer MD.Davison JM 2001).  
Hydralazine is safe and used frequently as adjunctive therapy with ┙ methyldopa and ┚ 
blockers. 
Calcium Channel Blockers such as Nifedipine, Nicardipine and Verapamile have been used 
in severe hypertension. They do not appear to be associated with any increase in congenital 
anomalies when used in the first trimester.  
Calcium channel blockers may potentiate the hypotensive effects and neuromuscular 
blockade of magnesium and the interaction should be kept in mind when the drugs are used 
in women with a possibility of developing preeclampsia (Dynder 1988).  
Labetalol appears to be as effective as methyldopa, but there is little follow up information 
on children born to mothers treated with this drug. 
The second and third trimester exposure to ACE inhibitors and AT1 antagonists may be 
associated with serious adverse fetal effects. Most of these problems have been disturbances 
of fetal and neonatal renal function, such as oligohydramnios, neonatal anuria, renal failure 
and death (Pryde 1993). The fetal outcome is generally good in women who present in early 
pregnancy while taking an ACE inhibitor if the drug is stopped.  
Continued administration of an ACE inhibitor during pregnancy is contraindicated (Shotan 
1994).  
www.intechopen.com
 
Sexual and Reproductive Function in Chronic Kidney Disease and Effect of Kidney Transplantation 
 
245 
The use of thiazide diuretics has been approved in women with chronic hypertension if 
prescribed before gestation; however, the recommendation is against their use in 
preeclamptic women, who often manifest decreased intravascular volumes and poor 
placental perfusion. 
3.7.3 Management of infection 
Pregnancy is associated with suppression of the adaptive immune system. There is evidence 
that pregnant women in general are more susceptible to infection. Infection also is an 
important consideration in any patient receiving immunosuppressive drugs, including 
transplant patients. 
3.7.3.1 Bacterial 
Urinary tract infections are the most common bacterial infections and occur in up to 40% of 
pregnant transplant recipients, and are particularly common in patients who develop end-
stage renal disease due to pyelonephritis. These women should have monthly screening 
urine cultures (Armenti, Constantinescu et al. 2008), if asymptomatic bacteriuria is present; 
the patient should be treated for 2 weeks and may be treated with suppressive doses of 
antibiotics for the rest of the pregnancy (Lessan-Pezeshki M 2002). If there is a need for 
invasive procedures such as fetal monitoring with scalp electrodes or intrauterine pressure 
monitoring, prophylactic antibiotics are recommended. Aseptic technique should be used 
for even minor surgery and steroid therapy augmented. 
3.7.3.2 Viral 
Cytomegalovirus (CMV) remains the most frequent cause of viral infection post 
transplantation, however if the patient waits the recommended time after transplantation to 
become pregnant, she has passed the peak time of risk for CMV infection. 
Infection in the fetus can be diagnosed by culturing the amniotic fluid. Titers of anti-CMV 
IgG and IgM during pregnancy are recommended, Ganciclovir has caused birth defects in 
animals when administered at twice human dose (Hou S and 1999). Herpes Simplex Virus 
(HSV) infection before 20 weeks gestation is associated with an increased rate of abortion. A 
positive HSV cervical culture at term is an indication for cesarean section. This can minimize 
the risk for neonatal herpes. Acyclovir can be safely used in pregnancy (Andrew 1992).  
Continuous exposure to CsA in utero seems to impair T-, B- and NK-cell development and 
function in neonates. This effect is prolonged throughout the first year of life. In addition, 
low levels of serum immunoglobulins occur at the same time. This leads to suggest a 
delayed administration of classical vaccinations (after the first 6 months of life) in view of 
the potential risks of both sub-optimal immunologic responses, and adverse events after the 
administration of live, attenuated vaccines in infants born from young female organ 
transplant recipients (Schen 2002). 
An infant born to an HBSAg – positive mother should be given hepatitis B immunoglobulin 
within 12 hours of birth and HBV vaccine at another site within 48 hours followed by a 
booster injection at 1 and 6 month. 
The combination of immunoglobulin and vaccine offers protection for more than 90% of 
infants. 
Vertical transmission is believed to be low (<7%) with hepatitis C unless the patient is also 
infected with the human immunodeficiency virus (Lessan-Pezeshki M 2002). 
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3.7.4 Labor and delivery 
The incidence of pre-term delivery is 50%, because of presence of preeclampsia, renal 
function deterioration, fetal distress, premature rupture of membrane and premature labor. 
Intrauterine uterine growth retardation showing small-for-age babies is present in 20% of 
pregnancies. In general, successful fetal outcome is related to better renal function at 
conception. Despite immunosuppressive therapy there is no increase of fetal abnormalities. 
A transplanted kidney rarely obstructs labor, vaginal delivery is recommended in most 
transplant recipient women. Cesarean section should be performed only for standard 
obstetric reasons. Delivery should occur in a specialized centre. Care must be taken to avoid 
fluid overload and infection. At the time of delivery, instrumentation should be minimized. 
Patients with renal insufficiency may be particularly at risk for water retention secondary to 
oxytocin (Lessan-Pezeshki M 2002). 
In the perinatal period, the steroid dose should be augmented to cover the stress of labor 
and to prevent postpartum rejection. Hydrocortisone, 100 mg every 6 hours, should be 
given during labor and delivery. In the puerperium, renal function, proteinuria, blood 
pressure, cyclosporine/tacrolimus blood levels and fluid balance should be closely 
monitored.  
3.7.5 Breastfeeding 
Breastfeeding is discouraged for patients taking any immunosuppressive drugs. 
Cyclosporine measurement in maternal blood and breast milk revealed a mean breast milk/ 
maternal blood level ratio of 84%  (Munoz-Flores- thiagarajan and 2001). 
Azathioprine is also appears in breast milk, these levels can be toxic to a newborn, and 
nursing is not recommended. Similar recommendations exist for tacrolimus or any other 
immunosuppressive agents. 
In summary, Because the outcome of pregnancy in transplantation are so different than 
those in chronic dialysis, it is advisable to treat end-stage renal disease patients with 
transplantation and wait until renal function has been stable for 1 to 2 years before 
undertaking a planned pregnancy. Such planned pregnancies offer the mother and fetus the 
best chance of favorable outcome. Before any woman with a renal transplant embarks on a 
pregnancy, she should be counseled by an obstetrician and transplant physician. Pregnancy 
appears to have no significant effect on graft function or survival; however, an important 
concern is that a mother may not survive to bring up the child that she bears. (Davison JM 
1987)  
3.8 Contraception for transplant patients: 
Most female transplant recipients are unaware that transplantation has reversed the relative 
infertility associated with end-stage renal disease. The incidence of unwanted pregnancy 
among female kidney transplant recipients is significantly higher than general population. 
An unplanned pregnancy puts this special group at higher risk; either an induced abortion 
or continuing the pregnancy without a preconceptional evaluation could be harmful 
(Lessan-Pezeshki and 2004). Outcomes for unwanted pregnancies are inferior to outcomes 
for planned pregnancies, so it is strongly advised that every sexually active transplant 
recipient attend a family-planning counseling session. Contraceptive counseling should be 
provided before transplantation surgery, because ovulatory cycles may begin within 1 to 2 
months after transplantation in women with grafts that are functioning well. Women who 
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do not desire pregnancy should be protected by an effective method of contraception. 
Surgical contraception (sterilization) should be considered for those who have completed 
their family. Tubal ligation can be performed at the time of transplantation surgery. 
Vasectomy is also an effective form of permanent contraception with little morbidity. The 
risk for infection may be increased with the use of an intrauterine device in immuno-
compromised patients, and their efficacy decrease because of anti-inflammatory effects of 
immunosuppressive agents (Zerner J, Doil KL et al. 1981). New devices containing 
levonorgestrel are more effective than previous copper containing devices, with fewer side 
effects (Fong and Singh 1999).  
Depot medroxyprogesterone acetate injection at three months interval is another effective 
method of contraception for these patients but return of fertility after discontinuation is not 
fast and loss of bone mineral density is a concern with its long-term use. 
Although low dose estrogen progesterone oral contraceptive preparations are not 
contraindicated for transplant patients, but they should be used with caution because they 
may cause or aggravate hypertension or precipitate thromboembolism, especially in the 
context of cyclosporine immunosuppression. Calcineurin inhibitors levels should also be 
monitored soon after the contraceptive is started. Because of unfounded fear of using 
contraceptive pills, a significant number of kidney transplant recipients use less effective 
methods such as coitus interruptus. In our study on unwanted pregnancy we found that 
92% of women with unwanted pregnancies were using coitus interruptus as the only 
method of contraception (Ghazizadeh 2005). Progestin-only pill is an option for women who 
have contraindication to use estrogen but their failure rate is higher than combined oral 
contraceptive pills. Barrier contraceptives such as male condom are the safest modality but 
depend on user compliance for efficacy. It provides some protection against sexually 
transmitted diseases. Patients should know about emergency contraception in case of a 
broken condom. Two tablets of 0.75 mg of Levonorgestrel pills are administered within 72 
hours of unprotected intercourse. Considering the above mentioned issues, unplanned 
pregnancy should be avoided by proper use of effective contraception. 
4. Conclusion 
Chronic kidney disease affects reproductive and sexual functions in both sexes. Although 
adequate dialysis will improve this dysfunction to some extent, but successful kidney 
transplantation has a better impact on fertility and reproductive functions.   
Reproductive success is a common, expected outcome for male and female recipients of 
kidney transplant. One of the most impressive aspects of successful renal transplantation in 
the young person is the ability of the male patient to father a child and the female patient to 
give birth to a healthy baby.  There are, however, important maternal and fetal 
complications that need to be considered to provide optimal care to the mother and her 
infant.  
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